Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to define the recommended dose of BMS-582664 that could be
safely combined with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) or 5-fluorouracil,
leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimens in patients with advanced
gastrointestinal malignancies and to evaluate the safety profile, tolerability,
pharmacokinetics (PK) and pharmacodynamics (PD) of these combinations.